NEOS Investment Management LLC Invests $436,000 in Corvus Pharmaceuticals, Inc. $CRVS

NEOS Investment Management LLC purchased a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 59,202 shares of the company’s stock, valued at approximately $436,000.

Other hedge funds have also added to or reduced their stakes in the company. Police & Firemen s Retirement System of New Jersey bought a new position in Corvus Pharmaceuticals during the second quarter worth about $49,000. Sender Co & Partners Inc. acquired a new stake in shares of Corvus Pharmaceuticals during the second quarter worth about $52,000. ProShare Advisors LLC bought a new position in shares of Corvus Pharmaceuticals during the 2nd quarter valued at about $54,000. Shelton Wealth Management LLC bought a new position in shares of Corvus Pharmaceuticals during the 3rd quarter valued at about $101,000. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Corvus Pharmaceuticals by 20.2% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 15,488 shares of the company’s stock valued at $62,000 after purchasing an additional 2,599 shares during the period. Institutional investors and hedge funds own 46.64% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on CRVS shares. Oppenheimer raised their target price on shares of Corvus Pharmaceuticals from $15.00 to $32.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. Wall Street Zen raised shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a report on Wednesday, January 21st. HC Wainwright upped their target price on shares of Corvus Pharmaceuticals from $11.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Finally, Jefferies Financial Group increased their target price on Corvus Pharmaceuticals from $13.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Corvus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $31.80.

Corvus Pharmaceuticals Stock Down 5.5%

Shares of CRVS stock opened at $16.57 on Friday. Corvus Pharmaceuticals, Inc. has a 12 month low of $2.54 and a 12 month high of $26.95. The company’s fifty day simple moving average is $13.64 and its 200-day simple moving average is $9.30. The firm has a market cap of $1.39 billion, a PE ratio of -31.26 and a beta of 0.73.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.